Publication

Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase

Journal Paper/Review - Jun 27, 2014

Schiff Michael H, von Kempis Johannes, Goldblum Ronald, Tesser John R, Müller Rüdiger